fda glp-1 warning october 2025 The has received hundreds of adverse event reports tied to compounded GLP-1s. PRI's brief warns that patients should know the risks before trusting knockoff versions. Read the brief: https://medecon.org/unauthorized-glp-1-knockoffs FDA Achieves Year 1 Goals

Any suspected adverse reactions should be reported via the MHRA Yellow Card scheme

This guide covers evidence-based recommendations for coffee consumption during semaglutide therapy, including timing strategies, preparation methods, and signs that temporary caffeine reduction may benefit your treatment experience

Rachele Pojedic, Chief Science Officer at Restore

How much tirzepatide per week

The authors noted that the studys design, while robust in terms of follow-up length and population diversity, was limited by the absence of hemoglobin A1c measurements and by the lack of GLP-1RA medications during participants follow-up period

Quick Answer Aetna's GLP-1 coverage in 2026: Wegovy & Zepbound (weight loss): Covered on most commercial Aetna plans with prior authorization